Regencor Announces Sean Edwards as new President & CEO

May 18, 2022


Company Update

San Carlos, CA. - May 18, 2022 - Regencor, Inc., a leading pre-clinical company in cardiac regeneration, announced today the appointment of Sean Edwards as President and CEO. Former CEO and co-founder Tom Okarma will remain with the company as Executive Chairman and continue his involvement with daily operations.Through 20 years of experience as an executive and lawyer, Mr. Edwards has helped businesses and clients navigate sophisticated strategic, legal, and regulatory issues. Working with both public and private companies, Mr. Edwards has expertise in growing business enterprises and successfully building shareholder value.“We are delighted to welcome Sean to Regencor” said Tom Okarma, Executive Chairman, and co-founder. “We are pleased that we have sufficiently matured as a company to attract a senior executive with Sean's proven track record. He has held multiple senior executive positions in biopharma and has experience managing finance, corporate development, operations, product development and large clinical trials. We are all excited to start working with Sean to accelerate Regencor's growth trajectory”.

“I'm excited to be joining Regencor at such a dynamic time” said Sean Edwards, CEO. “Having worked across several therapeutic areas during my career, I haven't seen many technologies that hold this much promise. Regencor's technology has the potential to be a tremendous leap forward in our ability to treat myocardial infarction and heart failure.”

Over the course of his career, Mr. Edwards has raised over $200M in institutional financings and has negotiated the acquisition and license of technologies and intellectual property. Experienced in guiding drugs and devices through the FDA, Mr. Edwards has also led the commercial launch of national and international brands in the physician dispensed and OTC drug channels. Prior to his career in life sciences, he spent eight years as an attorney specializing in complex commercial litigation for national and international law firms.

About Regencor

Regencor is a privately held spin-out of Stanford University that has received multiple awards from the National Institutes of Health and the California Institute for Regenerative Medicine. Its lead product is a first-in-class, proprietary biologic that stimulates cardiac regeneration after myocardial infarction (heart attack). The recombinant protein drives the proliferation of heart muscle and vascular cells exclusively within the infarct zone, resulting in a substantial reduction in scar volume and the sustained clinical improvement of heart function in large animals with and without comorbidities. The specific parameters of functional improvement reduce the incidence of Major Adverse Cardiac Events (MACE), which are the traditional outcome measures in randomized clinical trials. The therapeutic is administered by non-invasive subcutaneous delivery and will be the world's first outpatient therapy to restore heart function after myocardial infarction.

Regencor's pipeline includes pre-clinical stage products under development for cardiomyopathy-associated heart failure discovered with their whole proteome screening platform.
To learn more about Regencor, please visit


Sean Edwards, President & CEO.

Tom Okarma, MD, PhD, Executive Chairman & Cofounder